GTx Initiates Phase I Clinical Trial For GTx-758, An Oral Luteinizing Hormone Inhibitor For Advanced Prostate Cancer
GTx, Inc. (NASDAQ: GTXI) announced today that it has initiated a Phase I clinical trial for GTx-758, an oral luteinizing hormone (LH) inhibitor to treat men with advanced prostate cancer. The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of GTx-758 using a single ascending dose, double blind, placebo controlled design in healthy male volunteers.
Subscribe to:
Posts (Atom)
